Credit Suisse’s CervoMed CRVO Stock Holding History

Credit Suisse’s Portfolio CRVO Stock Details CRVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-53	Closed	-$1K	–	4077
2022 Q2	$1K	Buy	+53	New	+$657	﹤0.01%	3814

Other funds holding CRVO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Credit Suisse's CRVO Position: Q3 2022 in Review

Credit Suisse sold out of CervoMed (CRVO) in Q3 2022, closing a stake of 53 shares — an estimated $1K sold.

Credit Suisse first reported a position in CRVO in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 12 funds tracked by Wall St. Rank hold CRVO as of Q3 2022.

Credit Suisse reported no remaining CervoMed position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 53 CervoMed shares in Q3 2022, an estimated $1K.
Credit Suisse first reported a position in CervoMed in Q2 2022 and held it in 1 quarter.
Credit Suisse's CervoMed position peaked at $1K in Q2 2022.
12 funds tracked by Wall St. Rank held CervoMed as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.